Plasma levels of phospholipase A2-IIA in patients with different types of malignancies: Prognosis and association with inflammatory and coagulation biomarkers

Pathology and Oncology Research

Volumn 19, Issue 4, 2013, Pages 839-846

  Menschikowski, Mario ^a   Hagelgans, Albert ^a   Schuler, Ulrich ^a   Froeschke, Susanne ^a   Rosner, Andrea ^a   Siegert, Gabriele ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

C reactive protein; Cancer; Fibrinogen; Inflammation; Secreted phospholipase A2

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 8; C REACTIVE PROTEIN; FIBRINOGEN; PHOSPHOLIPASE A2 GROUP II; PHOSPHOLIPASE A2 GROUP IIA; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BLOOD CLOTTING DISORDER; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; ESOPHAGUS CANCER; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; INFLAMMATION; LIVER CELL CARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PANCREAS CANCER; PROTEIN BLOOD LEVEL; STOMACH CANCER; UPREGULATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD COAGULATION FACTORS; C-REACTIVE PROTEIN; FEMALE; GROUP II PHOSPHOLIPASES A2; HUMANS; INFLAMMATION; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84885144972     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-013-9652-y     Document Type: Article

References (53)

1. Menschikowski M, Hagelgans A, Siegert G (2006) Secretory phospholipase A2 of group IIA: is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases? Prostaglandins Other Lipid Mediat 79:1-33
2. Triggiani M, Granata F, Giannattasio G, Marone G (2005) Secretory phospholipases A2 in inflammatory and allergic diseases: not just enzymes. J Allergy Clin Immunol 116:1000-1006
3. Scott KF, Sajinovic M, Hein J, Nixdorf S, Galettis P, Liauw W, de Souza P, Dong Q, Graham GG, Russell PJ (2010) Emerging roles for phospholipase A2 enzymes in cancer. Biochimie 92:601-610
4. Mirtti T, Laine VJO, Hiekkanen H, Hurme S, Rowe O, Nevalainen TJ, Kallajoki M, Alanen K (2009) Group IIA phospholipase A2 as a prognostic marker in prostate cancer: relevance to clinicopathological variables and disease-specific mortality. Acta Pathol Microbiol Immunol Scand 117:151-161
5. Laye JP, Gill JH (2003) Phospholipase A2 expression in tumours: a target for therapeutic intervention? Drug Discov Today 8:710-716
6. Yamashita S, Yamashita J, Sakamoto K, Inada K, Nakashima Y, Murata K, Saishoji T, Nomura K, Ogawa M (1993) Increased expression of membrane-associated phospholipase A2 shows malignant potential of human breast cancer cells. Cancer 71:3058-3064
7. Asano T, Shoda J, Ueda T, Kawamoto T, Todoroki T, Shimonishi M, Tanabe T, Sugimoto Y, Ichikawa A, Mutoh M, Tanaka N, Miwa M (2002) Expressions of cyclooxygenase-2 and prostaglandin E-receptors in carcinoma of the gallbladder: crucial role of arachidonate metabolism in tumor growth and progression. Clin Cancer Res 8:1157-1167
8. Ogawa M, Yamashita S, Sakamoto K, Ikei S (1991) Elevation of serum group II phospholipase A2 in patients with cancers of digestive organs. Res Commun Chem Pathol Pharmacol 74:241-244
9. Yamashita S, Ogawa M, Sakamoto K, Abe T, Arakawa H, Yamashita J (1994) Elevation of serum group II phospholipase A2 levels in patients with advanced cancer. Clin Chim Acta 228:91-99
10. Oleksowicz L, Liu Y, Bracken RB, Gaitonde K, Burke B, Succop P, Levin L, Dong Z, Lu S (2012) Secretory phospholipase A2-IIa is a target gene of the HER/HER2-elicited pathway and a potential plasma biomarker for poor prognosis of prostate cancer. Prostate 72:1140-1149
11. Kupert E, Anderson M, Liu Y, Succop P, Levin L, Wang J, Wikenheiser-Brokamp K, Chen P, Pinney SM, Macdonald T, Dong Z, Starnes S, Lu S (2011) Plasma secretory phospholipase A2-IIA as a potential biomarker for lung cancer in patients with solitary pulmonary nodules. BMC Cancer 11:513
12. Nevalainen TJ, Haapamäki MM, Grönroos JM (2000) Roles of secretory phospholipases A2 in inflammatory diseases and trauma. Biochim Biophys Acta 1488:83-90
13. Kallajoki M, Alanen KA, Nevalainen M, Nevalainen TJ (1998) Group II phospholipase A2 in human male reproductive organs and genital tumors. Prostate 35:263-272
14. Abe T, Sakamoto K, Kamohara H, Hirano Y, Kuwahara N, Ogawa M (1997) Group II phospholipase A2 is increased in peritoneal and pleural effusions in patients with various types of cancer. Int J Cancer 74:245-250
15. Nevalainen TJ (1993) Serum phospholipase A2 in inflammatory disease. Clin Chem 39:2453-2459
16. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539-545
17. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860-867
18. Moore MM, Chua W, Charles KA, Clarke SJ (2010) Inflammation and cancer: causes and consequences. Clin Pharmacol Ther 87:504-508
19. Roxburgh CS, McMillan DC (2010) Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 6:149-163
20. Mahmoud FA, Rivera NI (2002) The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep 4:250-255
21. McCall P, Catlow J, McArdle PA, McMillan DC, Edwards J (2011) Tumoral C-reactive protein and nuclear factor kappa-B expression are associated with clinical outcome in patients with prostate cancer. Cancer Biomark 10:91-99
22. Auwerda JJ, Sonneveld P, de Maat MP, Leebeek FW (2007) Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma. Haematologica 92:279-280
23. Battistelli S, Stefanoni M, Lorenzi B, Dell'avanzato R, Varrone F, Pascucci A et al (2008) Coagulation factor levels in non-metastatic colorectal cancer patients. Int J Biol Markers 23:36-41
24. Minnema MC, Fijnheer R, De Groot PG, Lokhorst HM (2003) Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost 1:445-449
25. Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, Bugge TH (2000) Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 96:3302-3309
26. Hanebutt FL, Rolf N, Loesel A, Kuhlisch E, Siegert G, Knoefler R (2008) Evaluation of desmopressin effects on haemostasis in children with congenital bleeding disorders. Haemophilia 14:524-530
27. Palumbo JS, Degen JL (2010) Mechanisms coupling the hemostatic system to colitis-associated cancer. Thromb Res 125(Suppl 2):S39-43
28. Yigit E, Gonullu G, Yucel I, Turgut M, Erdem D, Cakar B (2008) Relation between hemostatic parameters and prognostic/predictive factors in breast cancer. Eur J Intern Med 19:602-607
29. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646-674
30. Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140:883-899
31. Menschikowski M, Hagelgans A, Fuessel S, Mareninova OA, Neumeister V, Wirth MP, Siegert G (2012) Serum levels of secreted group IIA phospholipase A2 in benign prostatic hyperplasia and prostate cancer: A biomarker for inflammation or neoplasia? Inflammation 35:1113-1138
32. Rintala EM, Nevalainen TJ (1993) Synovial-type (group II) phospholipase A2 in serum of febrile patients with haematological malignancy. Eur J Haematol 50:11-16
33. Orlowski RZ, Baldwin AS Jr (2002) NF-κB as a therapeutic target in cancer. Trends Mol Med 8:385-389
34. Grivennikov SI, Karin M (2010) Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 21:11-19
35. Fan Y, Dutta J, Gupta N, Fan G, Gélinas C (2008) Regulation of programmed cell death by NF-κB and its role in tumorigenesis and therapy. Adv Exp Med Biol 615:223-250
36. Voleti B, Agrawal A (2005) Regulation of basal and induced expression of C-reactive protein through an overlapping element for OCT-1 and NF-κB on the proximal promoter. J Immunol 175:3386-3390
37. Begbie M, Notley C, Tinlin S, Sawyer L, Lillicrap D (2000) The Factor VIII acute phase response requires the participation of NF-κB and C/EBP. Thromb Haemost 84:216-222
38. Minnema MC, Chang AC, Jansen PM, Lubbers YT, Pratt BM, Whittaker BG et al (2000) Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood 95:1117-1123
39. Oelschläger C, Römisch J, Staubitz A, Stauss H, Leithäuser B, Tillmanns H, Hölschermann H (2002) Antithrombin III inhibits nuclear factor κB activation in human monocytes and vascular endothelial cells. Blood 99:4015-4020
40. Kim TH, Bae JS (2010) Inhibitory effects of antithrombin on the expression of secretory group IIA phospholipase A2 in endothelial cells. BMB Rep 43:604-608
41. Adams RA, Schachtrup C, Davalos D, Tsigelny I, Akassoglou K (2007) Fibrinogen signal transduction as a mediator and therapeutic target in inflammation: lessons from multiple sclerosis. Curr Med Chem 14:2925-2936
42. Rubel C, Gómez S, Fernández GC, Isturiz MA, Caamaño J, Palermo MS (2003) Fibrinogen-CD11b/CD18 interaction activates the NF-κB pathway and delays apoptosis in human neutrophils. Eur J Immunol 33:1429-1438
43. Fuller GM, Zhang Z (2001) Transcriptional control mechanism of fibrinogen gene expression. Ann N Y Acad Sci 936:469-479
44. 2 increases with prostate tumor grade. Clin Cancer Res 7:3857-3861
45. Jiang J, Neubauer BL, Graff JR, Chedid M, Thomas JE, Roehm NW et al (2002) Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma. Am J Pathol 160:667-671
46. Morgenbesser SD, McLaren RP, Richards B, Zhang M, Akmaev VR, Winter SF et al (2007) Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model. Prostate 67:83-106
47. 2 in prostate cancer. Cancer Res 64:6934-6940
48. Baden LR, Bensinger W, Angarone M, Casper C, Dubberke ER, Freifeld AG, Garzon R, Greene JN, Greer JP, Ito JI, Karp JE, Kaul DR, King E, Mackler E, Marr KA, Montoya JG, Morris-Engemann A, Pappas PG, Rolston K, Segal B, Seo SK, Swaminathan S, Naganuma M, Shead DA (2012) Prevention and treatment of cancer-related infections. J Natl Compr Cancer Netw 10:1412-1445
49. Buhmeida A, Bendardaf R, Hilska M, Laine J, Collan Y, Laato M, Syrjänen K, Pyrhönen S (2009) PLA2 (group IIA phospholipase A2) as a prognostic determinant in stage II colorectal carcinoma. Ann Oncol 20:1230-1235
50. Ganesan K, Ivanova T, Wu Y, Rajasegaran V, Wu J, Lee MH et al (2008) Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene. Cancer Res 68:4277-4286
51. Birts CN, Barton CH, Wilton DC (2010) Catalytic and non-catalytic functions of human IIA phospholipase A2. Trends Biochem Sci 35:28-35
52. Menschikowski M, Hagelgans A, Gussakovsky E, Kostka H, Paley EL, Siegert G (2008) Differential expression of secretory phospholipases A2 in normal and malignant prostate cell lines: regulation by cytokines, cell signaling pathways, and epigenetic mechanisms. Neoplasia 10:279-286
53. Menschikowski M, Hagelgans A, Kostka H, Eisenhofer G, Siegert G (2008) Involvement of epigenetic mechanisms in the regulation of secreted phospholipase A2 expressions in Jurkat leukemia cells. Neoplasia 10:1195-1203